Otera Capital Inc.

Canadalacaisse.com/fr/investissements/revenu-fixe/credit-immobilier

Its role Investor / Financier

project tracked
1
partner companies
4
news article
1

Otera Capital, operating as Otéra Capital or Otera Capital Inc., serves as the specialized commercial real estate debt financing division of Caisse de dépôt et placement du Québec (CDPQ), Canada's leading pension fund and institutional investor. Headquartered in Montreal, Quebec, the firm provides a comprehensive suite of financing products including construction loans, term loans, bridge loans, and land loans tailored to commercial real estate projects.

Read more

It focuses on sectors such as office, industrial, multifamily, life sciences, retail, and mixed-use developments, with operations spanning North America through offices in Montreal (headquarters), Toronto, and New York. The company emphasizes vertically integrated expertise in underwriting, asset management, and structuring complex deals, enabling it to support large-scale urban transformation projects.

With roots in CDPQ's real estate lending activities dating to 1967 and formalized as a dedicated entity around 2008, Otera Capital manages a multi-billion-dollar loan portfolio. In 2024, CDPQ integrated its real estate subsidiaries, incorporating Otera's investment teams while preserving the brand for ongoing market activities. This positions Otera Capital as a dominant player in Canadian CRE debt markets and a key institutional lender across the United States and Canada.

Also known as Otéra Capital and 9197-5169 Québec Inc..

The project Otera Capital is involved in

chemXplore tracks 1 project involving Otera Capital.

Roche Genentech Innovation Center Boston
Phase
Operational / Completed
Where
United States
Partners
Breakthrough Properties , Genentech , Roche , Tishman Speyer

Otera Capital in chemical industry news

17 September 2026
Roche Genentech Innovation Center Boston opens in Allston

Allston hub will focus on cardiovascular, renal and metabolic R&D, combine discovery-to-clinical work with AI and data science, and is part of a USD 50bn US investment programme.

Where its projects are

active all projects